Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy

Purpose Chronic peripheral neuropathy is a major adverse response to oxaliplatin-containing chemotherapy regimens, but there are no established risk factors pertaining to it. We investigated the efficacy of hyperacute peripheral neuropathy (HAPN) as a predictor of oxaliplatin-induced persistent peri...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Supportive care in cancer 2017-05, Vol.25 (5), p.1383-1389
Hauptverfasser: Tanishima, Hiroyuki, Tominaga, Toshiji, Kimura, Masamichi, Maeda, Tsunehiro, Shirai, Yasutsugu, Horiuchi, Tetsuya
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1389
container_issue 5
container_start_page 1383
container_title Supportive care in cancer
container_volume 25
creator Tanishima, Hiroyuki
Tominaga, Toshiji
Kimura, Masamichi
Maeda, Tsunehiro
Shirai, Yasutsugu
Horiuchi, Tetsuya
description Purpose Chronic peripheral neuropathy is a major adverse response to oxaliplatin-containing chemotherapy regimens, but there are no established risk factors pertaining to it. We investigated the efficacy of hyperacute peripheral neuropathy (HAPN) as a predictor of oxaliplatin-induced persistent peripheral neuropathy (PPN). Methods Forty-seven cases of stage III colorectal cancer who received adjuvant chemotherapy with oxaliplatin after curative surgery between January 2010 and August 2014 were retrospectively reviewed. HAPN was defined as acute peripheral neuropathy (APN) occurring on day 1 (≤24 h after oxaliplatin infusion) of the first cycle. PPN was defined as neuropathy lasting >1 year after oxaliplatin discontinuation. Results The average total dose of oxaliplatin was 625.8 mg/m 2 , and the average relative dose intensity was 66.7%. Twenty-two of the 47 patients (46.8%) had PPN and 13 (27.7%) had HAPN. Male sex, treatment for neuropathy, HAPN, and APN were significantly more frequent in patients with PPN ( p  = 0.013, 0.02,
doi_str_mv 10.1007/s00520-016-3514-6
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1846367027</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A550952134</galeid><sourcerecordid>A550952134</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-4a8361913a5565de8399f85f2ed6da5dd67417b1ac35f116274fa34e1636b3043</originalsourceid><addsrcrecordid>eNp1kUtv3CAUhVHVqJkm_QHdVJa66cYpl6e9jKK2qRSpm2aNGHM9IfKAC1jq_PtgTdKXUrGAC985XDiEvAV6AZTqj5lSyWhLQbVcgmjVC7IBwXmrOe9fkg3tBbSCS3lKXud8TyloLdkrcsp0z4AxsSG768OMyQ5LwaYu_HxXq6kJuKQ423J3aHxubDMndH4oMTVxbOJPO_l5ssWH1ge3DOhWbfa5YCjP25yTk9FOGd88zmfk9vOn71fX7c23L1-vLm_aQfC-tMJ2XEEP3EqppMOO9_3YyZGhU85K55QWoLdgBy5HAMW0GC0XCIqrLaeCn5EPR985xR8L5mL2Pg84TTZgXLKBTlRUU6Yr-v4f9D4uKdTuKtVxoXlP6W9qZyc0Poyx1O9aTc2llLSXDPh67cUzVB0O936IAUdf9_8SwFEwpJhzwtHMye9tOhigZg3XHMM1NVyzhmtU1bx7bHjZ7tH9UjylWQF2BHI9CjtMf7zov64P0f6uMw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1883473900</pqid></control><display><type>article</type><title>Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Tanishima, Hiroyuki ; Tominaga, Toshiji ; Kimura, Masamichi ; Maeda, Tsunehiro ; Shirai, Yasutsugu ; Horiuchi, Tetsuya</creator><creatorcontrib>Tanishima, Hiroyuki ; Tominaga, Toshiji ; Kimura, Masamichi ; Maeda, Tsunehiro ; Shirai, Yasutsugu ; Horiuchi, Tetsuya</creatorcontrib><description>Purpose Chronic peripheral neuropathy is a major adverse response to oxaliplatin-containing chemotherapy regimens, but there are no established risk factors pertaining to it. We investigated the efficacy of hyperacute peripheral neuropathy (HAPN) as a predictor of oxaliplatin-induced persistent peripheral neuropathy (PPN). Methods Forty-seven cases of stage III colorectal cancer who received adjuvant chemotherapy with oxaliplatin after curative surgery between January 2010 and August 2014 were retrospectively reviewed. HAPN was defined as acute peripheral neuropathy (APN) occurring on day 1 (≤24 h after oxaliplatin infusion) of the first cycle. PPN was defined as neuropathy lasting &gt;1 year after oxaliplatin discontinuation. Results The average total dose of oxaliplatin was 625.8 mg/m 2 , and the average relative dose intensity was 66.7%. Twenty-two of the 47 patients (46.8%) had PPN and 13 (27.7%) had HAPN. Male sex, treatment for neuropathy, HAPN, and APN were significantly more frequent in patients with PPN ( p  = 0.013, 0.02, &lt;0.001, and 0.023, respectively). There was no significant difference in the total oxaliplatin dose between patients with and without PPN ( p  = 0.061). Multivariate analyses revealed total dose of oxaliplatin and HAPN as independent predictors of PPN [ p  = 0.015; odds ratio (OR) = 1.005, 95% confidence interval (CI), 1.001–1.009 and p  = 0.001; OR = 75.307, 5.3–1070.123, respectively]. The total dose of oxaliplatin was relatively lower in patients with HAPN than that in those without HAPN in the PPN-positive group (not significant, p  = 0.068). Conclusion HAPN was found to be a predictor of oxaliplatin-induced PPN.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-016-3514-6</identifier><identifier>PMID: 27921224</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adjuvant chemotherapy ; Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - administration &amp; dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cancer ; Chemotherapy ; Chemotherapy, Adjuvant ; Chronic Disease ; Colorectal cancer ; Colorectal Neoplasms - drug therapy ; Female ; Fluorouracil - administration &amp; dosage ; Fluorouracil - adverse effects ; Hospital patients ; Humans ; Leucovorin - administration &amp; dosage ; Leucovorin - adverse effects ; Male ; Medical research ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Multivariate Analysis ; Nursing ; Nursing Research ; Oncology ; Organoplatinum Compounds - administration &amp; dosage ; Organoplatinum Compounds - adverse effects ; Original Paper ; Pain Medicine ; Peripheral Nervous System Diseases - chemically induced ; Peripheral neuropathy ; Predictive Value of Tests ; Registered nurses ; Rehabilitation Medicine ; Retrospective Studies ; Risk Factors ; Side effects</subject><ispartof>Supportive care in cancer, 2017-05, Vol.25 (5), p.1383-1389</ispartof><rights>Springer-Verlag Berlin Heidelberg 2016</rights><rights>COPYRIGHT 2017 Springer</rights><rights>Supportive Care in Cancer is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-4a8361913a5565de8399f85f2ed6da5dd67417b1ac35f116274fa34e1636b3043</citedby><cites>FETCH-LOGICAL-c439t-4a8361913a5565de8399f85f2ed6da5dd67417b1ac35f116274fa34e1636b3043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00520-016-3514-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00520-016-3514-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27928,27929,41492,42561,51323</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27921224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanishima, Hiroyuki</creatorcontrib><creatorcontrib>Tominaga, Toshiji</creatorcontrib><creatorcontrib>Kimura, Masamichi</creatorcontrib><creatorcontrib>Maeda, Tsunehiro</creatorcontrib><creatorcontrib>Shirai, Yasutsugu</creatorcontrib><creatorcontrib>Horiuchi, Tetsuya</creatorcontrib><title>Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Purpose Chronic peripheral neuropathy is a major adverse response to oxaliplatin-containing chemotherapy regimens, but there are no established risk factors pertaining to it. We investigated the efficacy of hyperacute peripheral neuropathy (HAPN) as a predictor of oxaliplatin-induced persistent peripheral neuropathy (PPN). Methods Forty-seven cases of stage III colorectal cancer who received adjuvant chemotherapy with oxaliplatin after curative surgery between January 2010 and August 2014 were retrospectively reviewed. HAPN was defined as acute peripheral neuropathy (APN) occurring on day 1 (≤24 h after oxaliplatin infusion) of the first cycle. PPN was defined as neuropathy lasting &gt;1 year after oxaliplatin discontinuation. Results The average total dose of oxaliplatin was 625.8 mg/m 2 , and the average relative dose intensity was 66.7%. Twenty-two of the 47 patients (46.8%) had PPN and 13 (27.7%) had HAPN. Male sex, treatment for neuropathy, HAPN, and APN were significantly more frequent in patients with PPN ( p  = 0.013, 0.02, &lt;0.001, and 0.023, respectively). There was no significant difference in the total oxaliplatin dose between patients with and without PPN ( p  = 0.061). Multivariate analyses revealed total dose of oxaliplatin and HAPN as independent predictors of PPN [ p  = 0.015; odds ratio (OR) = 1.005, 95% confidence interval (CI), 1.001–1.009 and p  = 0.001; OR = 75.307, 5.3–1070.123, respectively]. The total dose of oxaliplatin was relatively lower in patients with HAPN than that in those without HAPN in the PPN-positive group (not significant, p  = 0.068). Conclusion HAPN was found to be a predictor of oxaliplatin-induced PPN.</description><subject>Adjuvant chemotherapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration &amp; dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Chronic Disease</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Female</subject><subject>Fluorouracil - administration &amp; dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Hospital patients</subject><subject>Humans</subject><subject>Leucovorin - administration &amp; dosage</subject><subject>Leucovorin - adverse effects</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Organoplatinum Compounds - administration &amp; dosage</subject><subject>Organoplatinum Compounds - adverse effects</subject><subject>Original Paper</subject><subject>Pain Medicine</subject><subject>Peripheral Nervous System Diseases - chemically induced</subject><subject>Peripheral neuropathy</subject><subject>Predictive Value of Tests</subject><subject>Registered nurses</subject><subject>Rehabilitation Medicine</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Side effects</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kUtv3CAUhVHVqJkm_QHdVJa66cYpl6e9jKK2qRSpm2aNGHM9IfKAC1jq_PtgTdKXUrGAC985XDiEvAV6AZTqj5lSyWhLQbVcgmjVC7IBwXmrOe9fkg3tBbSCS3lKXud8TyloLdkrcsp0z4AxsSG768OMyQ5LwaYu_HxXq6kJuKQ423J3aHxubDMndH4oMTVxbOJPO_l5ssWH1ge3DOhWbfa5YCjP25yTk9FOGd88zmfk9vOn71fX7c23L1-vLm_aQfC-tMJ2XEEP3EqppMOO9_3YyZGhU85K55QWoLdgBy5HAMW0GC0XCIqrLaeCn5EPR985xR8L5mL2Pg84TTZgXLKBTlRUU6Yr-v4f9D4uKdTuKtVxoXlP6W9qZyc0Poyx1O9aTc2llLSXDPh67cUzVB0O936IAUdf9_8SwFEwpJhzwtHMye9tOhigZg3XHMM1NVyzhmtU1bx7bHjZ7tH9UjylWQF2BHI9CjtMf7zov64P0f6uMw</recordid><startdate>20170501</startdate><enddate>20170501</enddate><creator>Tanishima, Hiroyuki</creator><creator>Tominaga, Toshiji</creator><creator>Kimura, Masamichi</creator><creator>Maeda, Tsunehiro</creator><creator>Shirai, Yasutsugu</creator><creator>Horiuchi, Tetsuya</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20170501</creationdate><title>Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy</title><author>Tanishima, Hiroyuki ; Tominaga, Toshiji ; Kimura, Masamichi ; Maeda, Tsunehiro ; Shirai, Yasutsugu ; Horiuchi, Tetsuya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-4a8361913a5565de8399f85f2ed6da5dd67417b1ac35f116274fa34e1636b3043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adjuvant chemotherapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration &amp; dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Chronic Disease</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Female</topic><topic>Fluorouracil - administration &amp; dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Hospital patients</topic><topic>Humans</topic><topic>Leucovorin - administration &amp; dosage</topic><topic>Leucovorin - adverse effects</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Organoplatinum Compounds - administration &amp; dosage</topic><topic>Organoplatinum Compounds - adverse effects</topic><topic>Original Paper</topic><topic>Pain Medicine</topic><topic>Peripheral Nervous System Diseases - chemically induced</topic><topic>Peripheral neuropathy</topic><topic>Predictive Value of Tests</topic><topic>Registered nurses</topic><topic>Rehabilitation Medicine</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Side effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanishima, Hiroyuki</creatorcontrib><creatorcontrib>Tominaga, Toshiji</creatorcontrib><creatorcontrib>Kimura, Masamichi</creatorcontrib><creatorcontrib>Maeda, Tsunehiro</creatorcontrib><creatorcontrib>Shirai, Yasutsugu</creatorcontrib><creatorcontrib>Horiuchi, Tetsuya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanishima, Hiroyuki</au><au>Tominaga, Toshiji</au><au>Kimura, Masamichi</au><au>Maeda, Tsunehiro</au><au>Shirai, Yasutsugu</au><au>Horiuchi, Tetsuya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2017-05-01</date><risdate>2017</risdate><volume>25</volume><issue>5</issue><spage>1383</spage><epage>1389</epage><pages>1383-1389</pages><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>Purpose Chronic peripheral neuropathy is a major adverse response to oxaliplatin-containing chemotherapy regimens, but there are no established risk factors pertaining to it. We investigated the efficacy of hyperacute peripheral neuropathy (HAPN) as a predictor of oxaliplatin-induced persistent peripheral neuropathy (PPN). Methods Forty-seven cases of stage III colorectal cancer who received adjuvant chemotherapy with oxaliplatin after curative surgery between January 2010 and August 2014 were retrospectively reviewed. HAPN was defined as acute peripheral neuropathy (APN) occurring on day 1 (≤24 h after oxaliplatin infusion) of the first cycle. PPN was defined as neuropathy lasting &gt;1 year after oxaliplatin discontinuation. Results The average total dose of oxaliplatin was 625.8 mg/m 2 , and the average relative dose intensity was 66.7%. Twenty-two of the 47 patients (46.8%) had PPN and 13 (27.7%) had HAPN. Male sex, treatment for neuropathy, HAPN, and APN were significantly more frequent in patients with PPN ( p  = 0.013, 0.02, &lt;0.001, and 0.023, respectively). There was no significant difference in the total oxaliplatin dose between patients with and without PPN ( p  = 0.061). Multivariate analyses revealed total dose of oxaliplatin and HAPN as independent predictors of PPN [ p  = 0.015; odds ratio (OR) = 1.005, 95% confidence interval (CI), 1.001–1.009 and p  = 0.001; OR = 75.307, 5.3–1070.123, respectively]. The total dose of oxaliplatin was relatively lower in patients with HAPN than that in those without HAPN in the PPN-positive group (not significant, p  = 0.068). Conclusion HAPN was found to be a predictor of oxaliplatin-induced PPN.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>27921224</pmid><doi>10.1007/s00520-016-3514-6</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0941-4355
ispartof Supportive care in cancer, 2017-05, Vol.25 (5), p.1383-1389
issn 0941-4355
1433-7339
language eng
recordid cdi_proquest_miscellaneous_1846367027
source MEDLINE; SpringerNature Journals
subjects Adjuvant chemotherapy
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer
Chemotherapy
Chemotherapy, Adjuvant
Chronic Disease
Colorectal cancer
Colorectal Neoplasms - drug therapy
Female
Fluorouracil - administration & dosage
Fluorouracil - adverse effects
Hospital patients
Humans
Leucovorin - administration & dosage
Leucovorin - adverse effects
Male
Medical research
Medicine
Medicine & Public Health
Middle Aged
Multivariate Analysis
Nursing
Nursing Research
Oncology
Organoplatinum Compounds - administration & dosage
Organoplatinum Compounds - adverse effects
Original Paper
Pain Medicine
Peripheral Nervous System Diseases - chemically induced
Peripheral neuropathy
Predictive Value of Tests
Registered nurses
Rehabilitation Medicine
Retrospective Studies
Risk Factors
Side effects
title Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T23%3A09%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperacute%20peripheral%20neuropathy%20is%20a%20predictor%20of%20oxaliplatin-induced%20persistent%20peripheral%20neuropathy&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Tanishima,%20Hiroyuki&rft.date=2017-05-01&rft.volume=25&rft.issue=5&rft.spage=1383&rft.epage=1389&rft.pages=1383-1389&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-016-3514-6&rft_dat=%3Cgale_proqu%3EA550952134%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1883473900&rft_id=info:pmid/27921224&rft_galeid=A550952134&rfr_iscdi=true